Stock

Here is why TherapeuticsMD jumped 300%

TherapeuticsMD Inc. (NASDAQ: TXMD) surged 300% after the women’s healthcare firm announced the signing of a definitive agreement to be purchased by an EW Healthcare Partners affiliate. EW Healthcare Partners is a private equity company committed to investing in fast-growing healthcare firms.

EW Healthcare Partners to acquire TherapeuticsMD for $177 million

According to the terms of the agreement, which has received 100% support from TXMD’s board, EW Healthcare Partners shall initiate a tender offer to purchase all outstanding TXMD shares in a cash consideration at $10 per share to complete a merger. The total value of the transaction is estimated to be around $177 million. The acquisition price is 367.3% higher than TXMD’s closing price on May 27, 2022.

CEO TherapeuticsMD Hugh O’Dowd said:

We are very pleased to enter into this agreement with EW Healthcare Partners. Together, we will continue empowering women of all ages through a therapeutic focus in family planning, reproductive health, and menopause management. We have a deep appreciation for EW Healthcare Partner’s depth of expertise and track record and know they will bring an incredible value of knowledge and strategic guidance.

With over $4 billion in money raised since its establishment, EW Healthcare Partners is among the oldest and largest private healthcare venture organizations. EW Healthcare Partners has invested in over 150 fast-growing healthcare companies in  Europe and the US in medical devices, pharmaceuticals, technology-enabled services, and diagnostics.

EW Healthcare Partners Evis Hursever commented:

We are pleased to welcome TherapeuticsMD to the EW Healthcare Partners portfolio and are deeply committed to the Company’s mission of advancing women’s health. EW Healthcare Partners has already made a significant investment in women’s health through its acquisition of Majorelle.

TherapeuticsMD is an opportunity for Majorelle to expand to the US

TherapeuticsMD is a once-in-a-lifetime chance for Majorelle to break into the US arena, and it fits perfectly with EW Healthcare’s ambitious goals to build a leading trans-Atlantic women’s health platform.

Majorelle chairman and senior advisor of EW Healthcare Partners Oliver Bohuon said:

We look forward to working together with the company’s management team to enhance the patient experience, improve operational efficiency and create one of a very few trans-Atlantic specialty pharma companies dedicated to women’s health.

The post Here is why TherapeuticsMD jumped 300% appeared first on Invezz.

Disclaimer: MonopolyWinnersUpdates.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 MonopolyWinnersUpdates.com. All Rights Reserved.

To Top